

Fig. S5




Fig. S5. ONC213 treatment alters mitochondrial membrane potential with ONC213 sensitivity determined by reliance on OXPHOS. a-c. MV4-11, MOLM-13, THP-1, and U937 AML cell lines and primary AML cells from patients (AML#231, AML#235, and AML#237), maintained in culture media supplemented with either glucose (Glu) or galactose (Gal), were treated with vehicle or ONC213 for 48 h and then analyzed by Annexin V-FITC/PI staining and flow cytometry analyses. *** $P < 0.001$ compared to the same ONC213 treatment concentration in glucose media.